SCHEMBL6132406

SCHEMBL6132406

COC(=O)c1ccc(-c2ccc(N3CCN([C@H]4CC[C@H](C5CCCCC5)CC4)CC3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 6/20 0.48
MBTD1 Q05BQ5 2/20 0.43
L3MBTL3 Q96JM7 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TP53BP1 Q12888 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
HRH3 Q9Y5N1 2/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
KDM4E B2RXH2 4/20 0.43
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132410 1.00 MEN1 (0.49) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL7317032 0.93 ALDH1A1 (0.52) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6134010 0.89 ALDH1A1 (0.49) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6134606 0.87 KMT2A (0.53) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6134608 0.87 KMT2A (0.53) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6134695 0.87 KMT2A (0.53) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6132191 0.85 MEN1 (0.50) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6132190 0.85 MEN1 (0.50) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6132707 0.85 KMT2A (0.70) MEN1KMT2AALDH1A1MBTD1L3MBTL3
SCHEMBL6132703 0.85 KMT2A (0.70) MEN1KMT2AALDH1A1MBTD1L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MEN1 1517/4885KMT2A 4695/4885ALDH1A1 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.